MedTrace Logo

Furosemide as Supportive Therapy for COVID-19 Respiratory Failure

NCT04588792 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-12-11

No results posted yet for this study

Summary

This double-blind, placebo-controlled, randomized, parallel-group phase 2/3 study will study the utility of nebulized furosemide for pulmonary inflammation in Intubated, mechanically ventilated Patients with COVID-19.

Conditions

Interventions

DRUG

Nebulized Furosemide

Furosemide administered by nebulization through the ventilator circuit

DRUG

Nebulized Saline

Saline administered by nebulization through the ventilator circuit

Sponsors & Collaborators

  • University Health Network, Toronto

    collaborator OTHER

  • Dr. John Muscedere

    lead OTHER

Principal Investigators

  • John Muscedere, MD · Queens University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-16
Primary Completion
2023-02-01
Completion
2023-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04588792 on ClinicalTrials.gov